{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:07:12Z","timestamp":1782918432384,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2012,9,25]],"date-time":"2012-09-25T00:00:00Z","timestamp":1348531200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Soc Psychiatry Psychiatr Epidemiol"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1007\/s00127-012-0586-6","type":"journal-article","created":{"date-parts":[[2012,9,24]],"date-time":"2012-09-24T14:51:09Z","timestamp":1348498269000},"page":"631-638","source":"Crossref","is-referenced-by-count":46,"title":["Description of long-term polypharmacy among schizophrenia outpatients"],"prefix":"10.1007","volume":"48","author":[{"given":"Jaana T.","family":"Suokas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaana M.","family":"Suvisaari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Haukka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasi","family":"Korhonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jari","family":"Tiihonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,25]]},"reference":[{"issue":"1","key":"586_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1093\/schbul\/sbp116","volume":"36","author":"RW Buchanan","year":"2010","unstructured":"Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, William Keller W (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36(1):71\u201393","journal-title":"Schizophr Bull"},{"key":"586_CR2","unstructured":"Finnish guidelines for treatment of schizophrenia. The Finnish Medical Society Duodecim and the Finnish Psychiatric Association. http:\/\/www.terveysportti.fi\/xmedia\/hoi\/hoi35050.pdf . Accessed 16 Nov 2010"},{"issue":"2 Suppl","key":"586_CR3","first-page":"1","volume":"161","author":"AF Lehman","year":"2004","unstructured":"Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J, American Psychiatric Association, Steering Committee on Practice Guidelines (2004) Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 161(2 Suppl):1\u201356","journal-title":"Am J Psychiatry"},{"key":"586_CR4","unstructured":"National institute for clinical excellence (NICE) (2009) Clinical Guideline CG82 Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG82NICEGuideline.pdf . Accessed 16 Nov 2010"},{"key":"586_CR5","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1176\/appi.ajp.2011.10060908","volume":"168","author":"SM Essock","year":"2011","unstructured":"Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covel NH (2011) Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Am J Psychiatry 168:702\u2013708","journal-title":"Am J Psychiatry"},{"issue":"7","key":"586_CR6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1176\/appi.ajp.2011.11050695","volume":"168","author":"CA Tamminga","year":"2011","unstructured":"Tamminga CA (2011) When is polypharmacy an advantage? Am J Psychiatry 168(7):663","journal-title":"Am J Psychiatry"},{"key":"586_CR7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.4088\/JCP.v63n0201","volume":"63","author":"SM Stahl","year":"2002","unstructured":"Stahl SM (2002) Antipsychotic polylpharmacy: squandering precious resources? J Clin Psychiatry 63:93\u201394","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"586_CR8","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/schbul\/sbn018","volume":"35","author":"CU Correll","year":"2009","unstructured":"Correll CU, Rummel-Klulge C, Corves C, Kane JM, Leucht S (2009) Antipsychotic combination vs. monotherapy in schizophrenia: a meta-analysis of randomized controlled trials. Schizophr Bull 35(2):443\u2013457","journal-title":"Schizophr Bull"},{"issue":"5","key":"586_CR9","doi-asserted-by":"crossref","first-page":"720","DOI":"10.4088\/JCP.v69n0505","volume":"69","author":"JS Chang","year":"2008","unstructured":"Chang JS, Ahn YM, Park HJ, Lee KY, Kim SH, Kang UG, Kim YS (2008) Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 69(5):720\u2013721","journal-title":"J Clin Psychiatry"},{"key":"586_CR10","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1017\/S1461145710000490","volume":"13","author":"WW Fleschhacker","year":"2010","unstructured":"Fleschhacker WW, Heikkinen ME, Olie J-P, Landsberg W, Dewaele P, McQuade RD, Loze J-Y, Hennicken D, Kerselaers WS (2010) Effects on adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 13:1115\u20131125","journal-title":"Int J Neuropsychopharmacol"},{"key":"586_CR11","doi-asserted-by":"crossref","first-page":"984","DOI":"10.4088\/JCP.v64n0902","volume":"64","author":"RE McCue","year":"2003","unstructured":"McCue RE, Waheed R, Urcuyo L (2003) Polypharmacy in patients with schizophrenia. J Clin Psychiatry 64:984\u2013989","journal-title":"J Clin Psychiatry"},{"key":"586_CR12","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","volume":"65","author":"R Ganguly","year":"2004","unstructured":"Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC (2004) Prevalence, trends and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998\u20132000. J Clin Psychiatry 65:1377\u20131388","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"586_CR13","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1093\/oxfordjournals.schbul.a007117","volume":"30","author":"B Janssen","year":"2004","unstructured":"Janssen B, Weinmann S, Berger M, Gaebel W (2004) Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 30(4):1023\u20131033","journal-title":"Schizophr Bull"},{"key":"586_CR14","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.schres.2005.01.015","volume":"77","author":"M Edlinger","year":"2005","unstructured":"Edlinger M, Hausmann A, Kemmler G, Kurz M, Kurzthaler I, Walch T, Walpoth M, Fleischhacker W (2005) Trends in the pharmacological treatment of patients with schizophrenia over a 12\u00a0year observation period. Schizophr Res 77:25\u201334","journal-title":"Schizophr Res"},{"key":"586_CR15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","volume":"5","author":"D Faries","year":"2005","unstructured":"Faries D, Ascher-Svanum H, Zhu B, Correl C, Kane J (2005) Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotic. BMC Psychiatry 5:26","journal-title":"BMC Psychiatry"},{"issue":"6","key":"586_CR16","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/01.yic.0000224785.68040.43","volume":"21","author":"C Barbui","year":"2006","unstructured":"Barbui C, Nose M, Mazzi MA, Thornicroft G, Schene A, Becker T, Bindman J, Leese M, Helm H, Koeter M, Weinmann S, Tansella M (2006) Persistence with polypharmacy and excessive dosing in patients with schizophrenia treated in four European countries. Int Clin Psychopharmacol 21(6):355\u2013362","journal-title":"Int Clin Psychopharmacol"},{"key":"586_CR17","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1176\/ps.2006.57.8.1094","volume":"57","author":"MH Chakos","year":"2006","unstructured":"Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, Patel JK, Tapp A, Keefe RS, Rosenheck RA (2006) Baseline use of concomitant psychotropic medications to treat schizophrenia in the CATIE trial. Psychiatr Serv 57:1084\u20131101","journal-title":"Psychiatr Serv"},{"issue":"7","key":"586_CR18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1176\/appi.ps.58.7.1007","volume":"58","author":"TP Gilmer","year":"2007","unstructured":"Gilmer TP, Dolder CR, Folsom DP, Mastin W, Jeste DV (2007) Antipsychotic polypharmacy trends among Medical beneficiaries with schizophrenia in San Diego county, 1999\u20132004. Psychiatr Serv 58(7):1007\u20131010","journal-title":"Psychiatr Serv"},{"issue":"2","key":"586_CR19","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1097\/01.pra.0000265773.03756.3e","volume":"13","author":"JL Megna","year":"2007","unstructured":"Megna JL, Kunwar AR, Mahlotra K, Sauro MD, Devitt PJ, Rashid A (2007) A study of polypharmacy with second generation antipsychotics in patients with severe and persistent mental illness. J Psychiatr Pract 13(2):129\u2013137","journal-title":"J Psychiatr Pract"},{"issue":"10","key":"586_CR20","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S1553-7250(08)34072-0","volume":"34","author":"JL G\u00f6ren","year":"2008","unstructured":"G\u00f6ren JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann R (2008) When is antipsychotic polypharmacy supported by research evidence? Implications for QI. Jt Comm J Qual Patient Saf 34(10):571\u2013582","journal-title":"Jt Comm J Qual Patient Saf"},{"issue":"6","key":"586_CR21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/01.pra.0000341890.05383.45","volume":"14","author":"AK Pandurangi","year":"2008","unstructured":"Pandurangi AK, Dalkilic A (2008) Polypharmacy with second-generation antipsychotics: a review of evidence. J Psychiatr Pract 14(6):345\u2013367","journal-title":"J Psychiatr Pract"},{"key":"586_CR22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.783","volume":"12","author":"AB Jaffe","year":"2003","unstructured":"Jaffe AB, Levine J (2003) Antipsychotic medication coprescribing in the large state hospital system. Pharmacoepidemiol Drug Saf 12:41\u201348","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"586_CR23","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/appi.ps.54.1.55","volume":"54","author":"A Tapp","year":"2003","unstructured":"Tapp A, Wood AE, Secrest L, Erdmann J, Cubberley L, Kilzieh N (2003) Combination antipsychotic therapy in clinical practice. Psychiatr Serv 54(1):55\u201359","journal-title":"Psychiatr Serv"},{"key":"586_CR24","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.schres.2006.02.023","volume":"84","author":"J Kreyenbuhl","year":"2006","unstructured":"Kreyenbuhl J, Valenstein M, McCarthy JF, Ganoczy D, Blow FC (2006) Long-term combination antipsychotic treatment in VA patients with schizophrenia. Schizophr Res 84:90\u201399","journal-title":"Schizophr Res"},{"key":"586_CR25","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","volume":"161","author":"F Centorrino","year":"2004","unstructured":"Centorrino F, Goren JL, Hennen J, Salvatore P, Kelleher J, Baldessarini R (2004) Multiple versus single antipsychotic agents for hospitalized psychiatric patient: case\u2013control study of risks versus benefits. Am J Psychiatry 161:700\u2013706","journal-title":"Am J Psychiatry"},{"issue":"1","key":"586_CR26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","volume":"28","author":"RE Clark","year":"2002","unstructured":"Clark RE, Bartels SJ, Mellman TA, Peacock WJ (2002) Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for State Mental Health Policy. Schizophr Bull 28(1):75\u201384","journal-title":"Schizophr Bull"},{"key":"586_CR27","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1192\/bjp.188.2.122","volume":"188","author":"M Joukamaa","year":"2006","unstructured":"Joukamaa M, Heli\u00f6vaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V (2006) Schizophrenia, neuroleptic medication and mortality. Br J Psychiatry 188:122\u2013127","journal-title":"Br J Psychiatry"},{"issue":"2","key":"586_CR28","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4088\/JCP.08m04818yel","volume":"71","author":"L Baandrup","year":"2010","unstructured":"Baandrup L, Gasse C, Jensen V, Glenthoj B, Nordentoft M, Lublin H, Fink-Jensen A, Lindhart A, Mortensen P (2010) Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case\u2013control study. J Clin Psychiatry 71(2):103\u2013108","journal-title":"J Clin Psychiatry"},{"key":"586_CR29","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S0140-6736(09)60742-X","volume":"374","author":"J Tiihonen","year":"2009","unstructured":"Tiihonen J, L\u00f6nnqvist J, Wahlbeck K, Klaukka T, Niskanen L, Tanskanen A, Haukka J (2009) 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study. Lancet 374:620\u2013627","journal-title":"Lancet"},{"issue":"5","key":"586_CR30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1001\/archgenpsychiatry.2011.1532","volume":"69","author":"J Tiihonen","year":"2012","unstructured":"Tiihonen J, Suokas J, Suvisaari J, Haukka J, Korhonen P (2012) Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 69(5):476\u2013483","journal-title":"Arch Gen Psychiatry"},{"key":"586_CR31","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1176\/appi.ajp.2011.10081224","volume":"168","author":"J Tiihonen","year":"2011","unstructured":"Tiihonen J, Haukka J, Haddad P, Patel M, Korhonen P (2011) A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 168:603\u2013609","journal-title":"Am J Psychiatry"},{"key":"586_CR32","unstructured":"ATC\/DDD Index 2006. http:\/\/www.whocc.no\/atc_ddd_index\/ . Accessed 24 Aug 2011"},{"key":"586_CR33","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/pds.1549","volume":"17","author":"LH Nielsen","year":"2008","unstructured":"Nielsen LH, L\u00f8kkegaard E, Andreasen AH, Keiding N (2008) Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf 17:384\u2013388","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"586_CR34","doi-asserted-by":"crossref","unstructured":"Pickar D, Vinik J, Bartko JJ (2008) Pharmacotherapy of schizophrenia patients: preponderance of off-label drug use. PLoS ONE 3(9):e3150","DOI":"10.1371\/journal.pone.0003150"},{"key":"586_CR35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v65n1203","volume":"65","author":"M Sernyak","year":"2004","unstructured":"Sernyak M, Rosenheck R (2004) Clinicians\u2019 reasons for antipsychotic coprescribing. J Clin Psychiatry 65:107\u2013117","journal-title":"J Clin Psychiatry"},{"key":"586_CR36","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1600-0447.2012.01835.x","volume":"125","author":"G L\u00e4ngle","year":"2012","unstructured":"L\u00e4ngle G, Steiner T, Weiser P, Schep W, Jaeger S, Pfiffner C, Frasch K, Eschweiler GW, Messer T, Croissant D, Becker T, Kilian R (2012) Effects of polypharmacy on outcome in patients with schizophrenia in routine psychiatric treatment. Acta Psychiatr Scand 125:372\u2013381","journal-title":"Acta Psychiatr Scand"},{"key":"586_CR37","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.schres.2008.08.017","volume":"106","author":"J Per\u00e4l\u00e4","year":"2008","unstructured":"Per\u00e4l\u00e4 J, Saarni SI, Ostamo A, Pirkola S, Haukka J, H\u00e4rk\u00e4nen T, Koskinen S, L\u00f6nnqvist J, Suvisaari J (2008) Geographic variation and sociodemographic characteristics of psychotic disorders in Finland. Schizophr Res 106:337\u2013347","journal-title":"Schizophr Res"},{"key":"586_CR38","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","volume":"138","author":"JA Gallego","year":"2012","unstructured":"Gallego JA, Bonetti J, Zhang J, Kane JM, Correll CU (2012) Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res 138:18\u201328","journal-title":"Schizophr Res"},{"key":"586_CR39","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/hup.1189","volume":"26","author":"F Terevnikov","year":"2011","unstructured":"Terevnikov F, Stenberg J, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, Joffe G (2011) Add-on mirtazapine improves depressive symptoms in schizophrenia: a douple-blind randomized placebo-controlled study with an open-label extension phase. Hum Psychopharmacol 26:188\u2013193","journal-title":"Hum Psychopharmacol"}],"container-title":["Social Psychiatry and Psychiatric Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-012-0586-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00127-012-0586-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00127-012-0586-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,29]],"date-time":"2024-04-29T18:55:29Z","timestamp":1714416929000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00127-012-0586-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9,25]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1007\/s00127-012-0586-6","relation":{},"ISSN":["0933-7954","1433-9285"],"issn-type":[{"value":"0933-7954","type":"print"},{"value":"1433-9285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,25]]}}}